Correlative Biomarker Analysis of the Phase II Study of Prexasertib, a Cell Cycle Checkpoint Kinase 1 (CHK1) Inhibitor, in BRCA Wild-Type (brcawt), Platinum-Resistant Recurrent, High-Grade Serous Ovarian Cancer (PR-HGSOC)
CANCER RESEARCH（2023）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined